
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics Inc. is experiencing robust growth in its Filspari product, with a 37% quarter-over-quarter increase in new patient start forms predicted for 4Q24, signaling strong market acceptance. The company's revised total net sales projection for 2025 has increased to $339.9 million, driven by anticipated regulatory events and expanding market opportunities for both focal segmental glomerulosclerosis and IgA nephropathy. Additionally, with anticipated peak revenue from Filspari projected to reach $975.9 million by 2033, complemented by a growing royalty revenue stream from European markets, Travere Therapeutics is positioned favorably within the biopharmaceutical sector.
Bears say
Travere Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from potential regulatory hurdles and market dynamics. The company is at risk due to the possibility of failing to secure regulatory approval for its candidate pegtibatinase and encountering clinical trial failures, while the commercial opportunity for its product FILSPARI may be limited by competition and pricing issues. Furthermore, the recent announcement of a voluntary enrollment pause in the HARMONY study to address manufacturing scale-up, combined with potential competitive pressures, raises concerns over the company's ability to meet financial forecasts and adequately sustain operations.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares